Yuviwel receives a positive CHMP opinion: what the growth results show

Yuviwel, the navepegritide medicine for achondroplasia, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The recommendation covers children aged two and older with genetically confirmed achondroplasia and open growth plates. Adopted on October 15 and published on October 16, it is a step toward European Union authorization. The European Commission’s decision is still pending. [1]

Reader offer · IQON Labs

Buy 1, Get 1 20% Off

Pick any two research compounds. Take 20% off the lower priced one.

20% OFF

Applied automatically at checkout, no code needed

Claim my 20% off →

In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.

Reported by The Peptide Digest. The IQON Labs reader offers are separate from the medicine and clinical research discussed here.

Why the growth plate matters

Achondroplasia begins with a change in the FGFR3 gene that makes a growth-regulating signal overactive. At the growth plate, where cartilage is formed and replaced by bone, that signal restricts the growth of long bones. Navepegritide is a prodrug: it releases C-type natriuretic peptide, or CNP, which acts through the NPR-B receptor to counter downstream effects of excessive FGFR3 signaling. It changes the balance of signals governing growth rather than repairing the gene itself. [2]

The proposed indication therefore centers on children whose growth plates remain open. In APPROACH, researchers tested whether the change in signaling translated into faster growth over a year. [1] [2]

The measured gain was a growth rate

APPROACH, published online in JAMA Pediatrics in November 2025, was a randomized, double-blind trial at 10 hospitals in seven countries. The paper describes it as phase 2b, while ClinicalTrials.gov lists phase 2/3. [2] [6] In it, 84 children aged two to 11 were assigned to navepegritide or placebo. There were 57 children in the active-treatment group and 27 in the placebo group. The trial followed the comparison for 52 weeks. Its identifier is NCT05598320. [2] [6]

At week 52, the adjusted annualized growth rate was 5.89 centimeters per year with navepegritide and 4.41 with placebo. The reported adjusted difference was 1.49 centimeters per year, with a 95% confidence interval of 1.05 to 1.93. That interval describes uncertainty around the estimated group difference. It is not a range of gains that every child can expect. [2] [6]

Annualized growth velocity expresses the height gained over the observation period as a yearly rate. Adult height was not measured. Two children in the navepegritide group withdrew before week 52. The analysis included all 84 randomized children and used multiple imputation to account for missing week-52 values. [2] [6]

Growing faster leaves other questions open

Height is only one part of achondroplasia. The condition can involve leg bowing, spinal problems and other complications that affect daily life. APPROACH therefore also examined body proportions, leg alignment and measures of physical functioning. Exploratory measures of lower-limb alignment favored navepegritide. The images showed changes in bone alignment, while the longer-term effect on the need for surgery remains unknown. [2]

Participants had not previously received treatments intended to alter stature or growth. The trial excluded children with closed growth plates, severe untreated sleep apnea, or certain anticipated surgical needs. Its results therefore describe a selected group of children aged two to 11, a narrower population than the proposed indication of age two and older with open growth plates. [1] [2] [6]

Side effects during the first year

During the 52-week comparison, serious adverse events occurred in three of 57 children receiving navepegritide and three of 27 receiving placebo. Investigators considered none of those serious events treatment related. Across all levels of severity, treatment-related adverse events were reported in 12 of 57 children receiving navepegritide and seven of 27 receiving placebo. [2]

Injection-site reactions occurred in 11 of 57 children with navepegritide and four of 27 with placebo, and were described as mild and transient. EMA also lists hypertrichosis, or abnormal hair growth, among the most common side effects, without giving a frequency for that effect. The trial’s size and one-year comparison leave uncertainty about uncommon or delayed harms. [1] [2]

In the extension from week 52 through week 104, all 82 participants received navepegritide. Eighty completed that period, which had no placebo comparator. [6]

The next decision is authorization

Ascendis Pharma funded APPROACH and was involved in designing and running the trial, handling the data and preparing the manuscript. [2]

The European Commission’s authorization decision is pending. Ascendis said on October 16 that it expects a decision in the fourth quarter of 2026 and, if authorization is granted, an initial German launch in the first quarter of 2027. [1] [14]

As the children grow older, the central clinical question is whether faster growth is accompanied by easier movement and fewer medical complications. Longer follow-up also has to show how much of the early height advantage persists into adulthood. [2] [6]